Skip to main content

Table 1 Baseline population – key parameter values

From: Economic evaluation of type 2 diabetes prevention programmes: Markov model of low- and high-intensity lifestyle programmes and metformin in participants with different categories of intermediate hyperglycaemia

Health state Diagnostic test Diagnostic criteria Prevalence Annual incidence of T2DM Annual cost of care (£, 2015) Utility (QALYs)
Normoglycaemia (NGT) Any of fasting blood glucose, post-load glucose or glycated haemoglobin Fasting glucose: <5.6 mmol/L
Post-load glucose: <7.0 mmol/L
HbA1c: <6.0 mmol/mol
   £773
[Gamma distribution, SE: £102.63]
0.768
[Beta distribution, SE: 0.10]
Impaired fasting glucose (IFG) Fasting blood glucose: blood glucose test after a period of fasting (typically overnight) Fasting glucose: 5.6-6.9 mmol/L Isolated IFG: 12.76%
IFG + IGT: 1.49%
IFG + HbA1c: 6.61%
IFG + IGT + HbA1c: 1.06%
3.55%
[Beta distribution, SE: 0.006]
£869
[Gamma distribution, SE: 104.56]
0.759
[Beta distribution, SE: 0.11]
Impaired glucose tolerance (IGT) Post-load glucose: blood glucose test 2 hours after consuming a drink containing 75 g of sugar 2 hour post-load glucose: 7.0-11.1 mmol/L Isolated IGT: 7.50%
IGT + HbA1c: 3.31%
4.54%
[Beta distribution, SE: 0.004]
£946
[Gamma distribution, SE: 101.52]
0.746
[Beta distribution, SE: 0.10]
HbA1c Glycated haemoglobin: blood test which estimates blood glucose levels over previous 2-3 months 6.0-6.4 mmol/mol Isolated HbA1c: 7.53% 3.56%
[Beta distribution, SE:0.017]
£869
[Gamma distribution, SE: 104.56]
0.759
[Beta distribution, SE: 0.11]
Type 2 Diabetes Mellitus (T2DM) Any of fasting blood glucose, post-load glucose or glycated haemoglobin Fasting glucose: >6.9 mmol/l
2 hour post-load glucose: >11.1 mmol/L
   £1,179-£2,939
Increasing linearly from Year 1-15
[Gamma distribution, SE: 270.00]
0.738
[Beta distribution, SE: 0.12]
  1. Parametric form and standard error of distribution used in probabilistic sensitivity analysis in italics
  2. Sources: Diagnostic criteria for HbA1c and IGT [26] and for IFG [27], prevalence [28], annual incidence type 2 Diabetes [10], costs [36,37,38,39], utilities [40]
\